{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:52:32Z","timestamp":1768902752185,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 221 - Project B10"],"award-info":[{"award-number":["TRR 221 - Project B10"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We retrospectively analyzed the safety and efficacy of cyclophosphamide (cyclo) for salvage treatment of chronic graft-versus-host disease (cGvHD) and cGvHD-associated (glomerulo-)nephritis at our center between 01\/2010 and 11\/2019. We identified 13 patients (pts) receiving cyclo for treatment of moderate (3\/13) and severe (6\/13) steroid-refractory cGvHD, cGvHD-associated (glomerulo-)nephritis (3\/13), or vasculitis-like CNS manifestation of cGvHD (1\/13). Cyclo was started on median day 509 (range 42\u20138193) after cGvHD onset; the median duration of application was 153\u00a0days (range 14\u2013486) with 2\/13 currently continuing treatment. The National Institute of Health organ grading and the intensity of immunosuppression (IS) were assessed at cyclo start and repeated after 3, 6, and 12\u00a0months. Response assessment was stopped at the start of any additional new IS. The median time of follow up was 407\u00a0days (range 86\u20131534). Best response was 1\/13 CR, 6\/13 PR, 4\/13 SD, 1\/13 MR, and 1\/13 PD (ORR 54%). Significant and durable response was observed especially in cGvHD-associated (glomerulo-)nephritis (3\/3). Infectious complications &gt;\u2009CTCAE grade III were observed in 3\/12 pts. During cyclo therapy, none of the pts suffered from recurrence of underlying malignancy. Overall, cyclo was relatively well tolerated and showed responses in heavily pretreated patients but requires further evaluation within clinical trials.<\/jats:p>","DOI":"10.1007\/s00277-020-04193-1","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T21:02:39Z","timestamp":1595797359000},"page":"2181-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis"],"prefix":"10.1007","volume":"99","author":[{"given":"Matthias A.","family":"Fante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Bergler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Wertheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,26]]},"reference":[{"issue":"17","key":"4193_CR1","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","volume":"117","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ (2011) Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium. Blood 117(17):4651\u20134657. https:\/\/doi.org\/10.1182\/blood-2010-11-319509","journal-title":"Blood"},{"issue":"8","key":"4193_CR2","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","volume":"108","author":"CJ Fraser","year":"2006","unstructured":"Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, Parker P, Forman S, Weisdorf D, Gurney JG, Baker KS (2006) Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant survivor study. Blood 108(8):2867\u20132873. https:\/\/doi.org\/10.1182\/blood-2006-02-003954","journal-title":"Blood"},{"issue":"2","key":"4193_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringd\u00e9n OT, Savani BN, Soci\u00e9 G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy P, P\u00e9rez-Sim\u00f3n JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornh\u00e4user M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR (2015) Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 21(2):266\u2013274. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.021","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4193_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","volume":"22","author":"M Arora","year":"2016","unstructured":"Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers MED, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, Pusic I, Lee SJ (2016) Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 22(3):449\u2013455. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"4193_CR5","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579. https:\/\/doi.org\/10.1056\/NEJMra1703472","journal-title":"N Engl J Med"},{"issue":"2","key":"4193_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR (2017) The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant 23(2):211\u2013234. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4193_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21(3):389\u2013401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"4193_CR8","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2010.06.015","volume":"16","author":"D Wolff","year":"2010","unstructured":"Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 16(12):1611\u20131628. https:\/\/doi.org\/10.1016\/j.bbmt.2010.06.015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4193_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","volume":"17","author":"D Wolff","year":"2011","unstructured":"Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E (2011) Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 17(1):1\u201317. https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4193_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.transci.2014.04.005","volume":"50","author":"HT Greinix","year":"2014","unstructured":"Greinix HT, Worel N, Just U, Knobler R (2014) Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 50(3):349\u2013357. https:\/\/doi.org\/10.1016\/j.transci.2014.04.005","journal-title":"Transfus Apher Sci"},{"issue":"21","key":"4193_CR11","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243\u20132250. https:\/\/doi.org\/10.1182\/blood-2017-07-793786","journal-title":"Blood"},{"issue":"10","key":"4193_CR12","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, L\u00fcbbert M, W\u00e4sch R, Scheid C, St\u00f6lzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gr\u00e4ff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, du J, Blazar BR, Arnold R, Kr\u00f6ger N, Passweg J, Halter J, Soci\u00e9 G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062\u20132068. https:\/\/doi.org\/10.1038\/leu.2015.212","journal-title":"Leukemia"},{"issue":"2","key":"4193_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","volume":"108","author":"C Cutler","year":"2006","unstructured":"Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2):756\u2013762. https:\/\/doi.org\/10.1182\/blood-2006-01-0233","journal-title":"Blood"},{"issue":"11","key":"4193_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6(11):638\u2013647. https:\/\/doi.org\/10.1038\/nrclinonc.2009.146","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"4193_CR15","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686\u20133696. https:\/\/doi.org\/10.1200\/JCO.2005.10.517","journal-title":"J Clin Oncol"},{"issue":"3","key":"4193_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14(3):925\u2013934. https:\/\/doi.org\/10.1200\/JCO.1996.14.3.925","journal-title":"J Clin Oncol"},{"key":"4193_CR17","doi-asserted-by":"publisher","unstructured":"Patel SS, Rybicki L, Pohlman B, Bolwell B, Gerds AT, Hamilton BK, Hanna R, Kalaycio M, Majhail NS, Sobecks R (2019) Comparative effectiveness of busulfan\/cyclophosphamide versus busulfan\/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol Stem Cell Ther. https:\/\/doi.org\/10.1016\/j.hemonc.2019.09.002","DOI":"10.1016\/j.hemonc.2019.09.002"},{"issue":"6","key":"4193_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71(6):955\u2013960. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200477","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4193_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1365-2125.2012.04223.x","volume":"74","author":"MS Joy","year":"2012","unstructured":"Joy MS, La M, Wang J et al (2012) Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol 74(3):445\u2013455. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04223.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4193_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","volume":"20","author":"K Raj","year":"2014","unstructured":"Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, Mclornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O\u2019Donnell P (2014) Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20(6):890\u2013895. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"4193_CR21","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","volume":"115","author":"L Luznik","year":"2010","unstructured":"Luznik L, Bola\u00f1os-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ (2010) High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115(16):3224\u20133230. https:\/\/doi.org\/10.1182\/blood-2009-11-251595","journal-title":"Blood"},{"issue":"7","key":"4193_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/sj.bmt.1704829","volume":"35","author":"J Mayer","year":"2005","unstructured":"Mayer J, Krejc\u00ed M, Doubek M et al (2005) Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 35(7):699\u2013705. https:\/\/doi.org\/10.1038\/sj.bmt.1704829","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4193_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.bmt.1703550","volume":"29","author":"I Pusic","year":"2002","unstructured":"Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR (2002) Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 29(8):709\u2013710. https:\/\/doi.org\/10.1038\/sj.bmt.1703550","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4193_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003088-200038040-00001","volume":"38","author":"AV Boddy","year":"2000","unstructured":"Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38(4):291\u2013304. https:\/\/doi.org\/10.2165\/00003088-200038040-00001","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"4193_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL et al (2018) EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53(11):1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4193_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"MED Flowers","year":"2015","unstructured":"Flowers MED, Martin PJ (2015) How we treat chronic graft-versus-host disease. Blood 125(4):606\u2013615. https:\/\/doi.org\/10.1182\/blood-2014-08-551994","journal-title":"Blood"},{"issue":"2","key":"4193_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.beha.2008.03.003","volume":"21","author":"A Tyndall","year":"2008","unstructured":"Tyndall A, Dazzi F (2008) Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol 21(2):281\u2013289. https:\/\/doi.org\/10.1016\/j.beha.2008.03.003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"4193_CR28","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70(11):1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"issue":"suppl_1","key":"4193_CR29","doi-asserted-by":"publisher","first-page":"i100","DOI":"10.1093\/rheumatology\/kew417","volume":"56","author":"LS Davis","year":"2017","unstructured":"Davis LS, Reimold AM (2017) Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford) 56(suppl_1):i100\u2013i113. https:\/\/doi.org\/10.1093\/rheumatology\/kew417","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"4193_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/bmt.2011.35","volume":"46","author":"GC Hildebrandt","year":"2011","unstructured":"Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D (2011) Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 46(10):1283\u20131295. https:\/\/doi.org\/10.1038\/bmt.2011.35","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4193_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000445031","volume":"91","author":"JC Schupp","year":"2016","unstructured":"Schupp JC, K\u00f6hler T, M\u00fcller-Quernheim J (2016) Usefulness of cyclophosphamide pulse therapy in interstitial lung diseases. Respiration 91(4):296\u2013301. https:\/\/doi.org\/10.1159\/000445031","journal-title":"Respiration"},{"issue":"1","key":"4193_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0163-7258(90)90049-8","volume":"47","author":"JM Patel","year":"1990","unstructured":"Patel JM (1990) Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther 47(1):137\u2013146. https:\/\/doi.org\/10.1016\/0163-7258(90)90049-8","journal-title":"Pharmacol Ther"},{"issue":"10","key":"4193_CR33","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","volume":"17","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Escoli R, Moroni G (2018) Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev 17(10):1022\u20131027. https:\/\/doi.org\/10.1016\/j.autrev.2018.04.007","journal-title":"Autoimmun Rev"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04193-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04193-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T23:13:15Z","timestamp":1627254795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04193-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,26]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4193"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04193-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,26]]},"assertion":[{"value":"9 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M Fante has received a travel grant from Neovii. D Wolff has received honoraria from Mallinckrodt, Novartis, Takeda, MACO and Neovii. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective analysis was approved by the institutional ethics committee of University Regensburg (#19\u20131585-104; 11\/2019) and in accordance with the Helsinki Declaration of 1975, as revised in 2008. All the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients have granted informed consent prior to inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}